Yu-Ming Ni is a Cardiology physician affiliated with Scripps Institution of Oceanography. OpenAlex indexes 11 publications with 233 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
18111 Brookhurst St Ste 5100
Fountain Valley, CA 927086728
Telephone
714-546-2238Provider last certified this registry record 7 Jul 2022.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
39 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year202519 payments
- Novo Nordisk IncProgram year20259 payments
- Amgen Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.3%Statin16.9%Atorvastatin Calcium56%Rosuvastatin Calcium36%Pravastatin Sodium6%Simvastatin2%Part D<11 patientsBeta blocker11.4%Metoprolol Succinate55%Metoprolol Tartrate20%Carvedilol17%Nebivolol Hcl4%Sotalol4%Part D<11 patients+ 18 more classes in this area
Blood & clotting
12.5%Factor Xa inhibitor10.8%Eliquis84%Xarelto16%Part D≥104 patientsP2Y12 inhibitor1.7%Clopidogrel74%Brilinta26%Part D<11 patientsMetabolism & gastrointestinal
6.4%SGLT2 inhibitor3.4%Jardiance59%Farxiga41%Part D≥29 patientsGLP-1 receptor agonist2.2%Ozempic58%Mounjaro42%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- THE DOCTOR-PATIENT-DEVICE COLLABORATIVE: A CARDIOMEMS QUALITY IMPROVEMENT PROJECT
Journal of the American College of Cardiology
2022 - Natural Supplements for COVID19—Background, Rationale, and Clinical Trials
Journal of Evidence-Based Integrative Medicine
2021 - THROMBOTIC MICROANGIOPATHY LEADING TO ACUTE SYSTOLIC HEART FAILURE ASSOCIATED WITH SCLERODERMA RENAL CRISIS
Journal of the American College of Cardiology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”